JP2022548250A - 甲状腺ホルモン受容体ベータアゴニスト化合物 - Google Patents

甲状腺ホルモン受容体ベータアゴニスト化合物 Download PDF

Info

Publication number
JP2022548250A
JP2022548250A JP2022516154A JP2022516154A JP2022548250A JP 2022548250 A JP2022548250 A JP 2022548250A JP 2022516154 A JP2022516154 A JP 2022516154A JP 2022516154 A JP2022516154 A JP 2022516154A JP 2022548250 A JP2022548250 A JP 2022548250A
Authority
JP
Japan
Prior art keywords
alkyl
groups
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548250A5 (https=
Inventor
エイ カーシュバーグ，トーステン
ハルコム，ランドール
シュー，インジー
アンソニー ロメロ，エフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of JP2022548250A publication Critical patent/JP2022548250A/ja
Publication of JP2022548250A5 publication Critical patent/JP2022548250A5/ja
Priority to JP2025177489A priority Critical patent/JP2026027279A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022516154A 2019-09-12 2020-09-11 甲状腺ホルモン受容体ベータアゴニスト化合物 Pending JP2022548250A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025177489A JP2026027279A (ja) 2019-09-12 2025-10-22 甲状腺ホルモン受容体ベータアゴニスト化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899581P 2019-09-12 2019-09-12
US62/899,581 2019-09-12
PCT/US2020/050497 WO2021050945A1 (en) 2019-09-12 2020-09-11 Thyroid hormone receptor beta agonist compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025177489A Division JP2026027279A (ja) 2019-09-12 2025-10-22 甲状腺ホルモン受容体ベータアゴニスト化合物

Publications (2)

Publication Number Publication Date
JP2022548250A true JP2022548250A (ja) 2022-11-17
JP2022548250A5 JP2022548250A5 (https=) 2023-09-08

Family

ID=74866716

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516154A Pending JP2022548250A (ja) 2019-09-12 2020-09-11 甲状腺ホルモン受容体ベータアゴニスト化合物
JP2025177489A Pending JP2026027279A (ja) 2019-09-12 2025-10-22 甲状腺ホルモン受容体ベータアゴニスト化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025177489A Pending JP2026027279A (ja) 2019-09-12 2025-10-22 甲状腺ホルモン受容体ベータアゴニスト化合物

Country Status (7)

Country Link
US (1) US12398127B2 (https=)
EP (1) EP4028008A4 (https=)
JP (2) JP2022548250A (https=)
CN (1) CN114375193B (https=)
AU (1) AU2020346057A1 (https=)
CA (1) CA3154391A1 (https=)
WO (1) WO2021050945A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
KR20220017917A (ko) 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
AU2021374988A1 (en) 2020-11-06 2023-06-15 Aligos Therapeutics, Inc. Bicyclic pyridazinones as thyroid hormone receptor beta (tr-beta) agonists
WO2022194278A1 (zh) * 2021-03-19 2022-09-22 南京明德新药研发有限公司 双环苯酚类化合物及其应用
CN116940566A (zh) * 2021-03-19 2023-10-24 南京明德新药研发有限公司 双环吡啶酮类化合物及其应用
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064369A1 (en) * 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
JP2009501759A (ja) * 2005-07-21 2009-01-22 エフ．ホフマン−ラ ロシュ アーゲー 甲状腺ホルモン受容体アゴニストとしてのピリダジノン誘導体
JP2015500212A (ja) * 2011-11-30 2015-01-05 チョンドゥ ディアオ ファーマシューティカル グループ カンパニー，リミテッド ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
WO2018075650A1 (en) * 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197307A (en) 1977-04-12 1980-04-08 Ciba-Geigy Corporation 2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents
EP0377903A3 (de) 1989-01-09 1991-07-17 Bayer Ag Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
ES2240017T3 (es) 1999-09-30 2005-10-16 Pfizer Products Inc. Derivados de 6-azauracilo como ligandos de receptores tiroideos.
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
EP1347959A1 (de) 2000-12-27 2003-10-01 Bayer Aktiengesellschaft Indol-derivate
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
FR2882750B1 (fr) 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
GB0608724D0 (en) 2006-05-03 2006-06-14 Karobio Ab Novel Pharmaceutical Compositions
GB0610322D0 (en) 2006-05-24 2006-07-05 Karobio Ab Novel pharmaceutical compositions
WO2008130637A1 (en) 2007-04-18 2008-10-30 New York University Hydrazide compounds as thyroid hormone receptor modulators and uses thereof
WO2009001359A2 (en) 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
FR2933979B1 (fr) 2008-07-15 2012-08-24 Pf Medicament Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
RU2527948C2 (ru) 2009-04-20 2014-09-10 Мицубиси Танабе Фарма Корпорейшн Новый агонист бета рецептора тиреоидного гормона
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
SG11201402004YA (en) 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
CN102898377B (zh) 2012-02-14 2016-01-20 南京圣和药业股份有限公司 一类酞嗪酮衍生物及其用途
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
CN105477636B (zh) 2015-10-16 2019-09-17 厦门大学 使用阿维菌素及其衍生物治疗代谢疾病的方法
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US11419878B2 (en) 2016-03-28 2022-08-23 Intercept Pharmaceuticals, Inc. Medicine obtained by combining FXR agonist and ARB
SMT202500241T1 (it) 2016-03-31 2025-07-22 Genfit Elafibranor per uso nel trattamento di colangite biliare primitiva
BR112018073460A2 (pt) 2016-05-25 2019-07-09 Akarna Therapeutics Ltd terapias combinadas usando moduladores do receptor farnesoide x (fxr)
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
US20210212968A1 (en) 2016-10-19 2021-07-15 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
WO2018103624A1 (zh) 2016-12-06 2018-06-14 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
JP7618384B2 (ja) 2017-02-21 2025-01-21 ジェンフィ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
WO2018167103A1 (en) 2017-03-13 2018-09-20 Genfit Pharmaceutical compositions for combination therapy
WO2018170173A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP7266531B2 (ja) 2017-04-18 2023-04-28 ジェンフィ エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ
WO2018208707A1 (en) 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US20210121493A1 (en) 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
CN111032884A (zh) 2017-08-25 2020-04-17 基恩菲特公司 非酒精性脂肪性肝病、非酒精性脂肪性肝炎和/或肝纤维化的非侵入性诊断
WO2019053235A1 (en) 2017-09-15 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
EP3684954B1 (en) 2017-09-18 2025-11-26 Genfit Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
JP7264906B2 (ja) 2017-11-01 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
EP3710599B1 (en) 2017-11-13 2024-07-17 Gilead Sciences, Inc. Method for staging liver fibrosis in nash patients
JP7156722B2 (ja) 2018-01-23 2022-10-19 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピリダジノン化合物
WO2019209738A1 (en) 2018-04-24 2019-10-31 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
CN112805005A (zh) 2018-08-24 2021-05-14 拓臻股份有限公司 甲状腺素受体β促效剂化合物
EP3844156A4 (en) 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. TREATMENT OF HEPATIC DISORDERS
NZ773110A (en) 2018-09-18 2024-11-29 Terns Inc Compounds for treating certain leukemias
EA202190661A1 (ru) 2018-09-18 2021-08-13 Метакрайн, Инк. Агонисты фарнезоидного х-рецептора для лечения заболевания
CA3113373A1 (en) 2018-10-12 2020-04-16 InventisBio Co., Ltd. Thyroid hormone receptor agonists
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
CN111484481A (zh) 2019-01-26 2020-08-04 察略盛医药科技(上海)有限公司 哒嗪酮类衍生物、其制备方法及其在医药上的用途
CN113474335B (zh) 2019-02-21 2024-12-03 南京瑞捷医药科技有限公司 化合物及其作为甲状腺激素受体激动剂的用途
KR20220017917A (ko) 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
WO2020228577A1 (zh) 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2020239076A1 (zh) 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
EP4003349A1 (en) 2019-07-23 2022-06-01 Novartis AG Combination treatment of liver diseases using fxr agonists
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
TW202128668A (zh) 2019-12-16 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 并環類衍生物、其製備方法及其在醫藥上的應用
US20210379043A1 (en) 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
US20210379040A1 (en) 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
AU2021359895A1 (en) 2020-10-15 2023-06-15 Eli Lilly And Company Polymorphs of an fxr agonist
CN114437034A (zh) 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
KR20230154806A (ko) 2021-01-14 2023-11-09 엔요 파마 Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
PE20240097A1 (es) 2021-03-03 2024-01-18 Terns Pharmaceuticals Inc Compuestos agonistas beta del receptor de la hormona tiroidea
WO2022194278A1 (zh) 2021-03-19 2022-09-22 南京明德新药研发有限公司 双环苯酚类化合物及其应用
EP4429637A1 (en) 2021-11-11 2024-09-18 Terns Pharmaceuticals, Inc. Treating liver disorders with an ssao inhibitor
CN119013027A (zh) 2021-11-11 2024-11-22 拓臻制药公司 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合
PE20241327A1 (es) 2021-11-11 2024-06-26 Terns Pharmaceuticals Inc Tratamiento de trastornos hepaticos con un agonista del thr-beta
WO2023220404A1 (en) 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Treatment of non-alcoholic steatohepatitis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064369A1 (en) * 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
JP2009501759A (ja) * 2005-07-21 2009-01-22 エフ．ホフマン−ラ ロシュ アーゲー 甲状腺ホルモン受容体アゴニストとしてのピリダジノン誘導体
JP2015500212A (ja) * 2011-11-30 2015-01-05 チョンドゥ ディアオ ファーマシューティカル グループ カンパニー，リミテッド ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
WO2018075650A1 (en) * 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KELLY, M. J. ET AL.: "Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57(10), JPN6024041102, 2014, pages 3912 - 3923, ISSN: 0005438196 *

Also Published As

Publication number Publication date
AU2020346057A1 (en) 2022-04-21
EP4028008A1 (en) 2022-07-20
JP2026027279A (ja) 2026-02-18
CN114375193B (zh) 2024-05-14
US12398127B2 (en) 2025-08-26
CN114375193A (zh) 2022-04-19
WO2021050945A1 (en) 2021-03-18
US20220356177A1 (en) 2022-11-10
CA3154391A1 (en) 2021-03-18
EP4028008A4 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
JP2022548250A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
EP3555070B1 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
KR102204804B1 (ko) 디히드로피라졸 gpr40 조절제
JP5897566B2 (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
US11203587B2 (en) Thyroid hormone receptor beta agonist compounds
US20240059682A1 (en) Thyroid hormone receptor beta agonist compounds
CN114149424B (zh) 用于治疗疾病的杂环化合物
JP2022532520A (ja) 癌を処置するための化合物
CN105814039A (zh) 氟苯基吡唑化合物
WO2020257527A1 (en) Compounds for inhibiting fgfr4
AU2017380492B2 (en) Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof
US10407406B2 (en) 2-halo-5-alkynyl-pyridyl nicotinic ligands
US20240208939A1 (en) Treatment of autoimmune and inflammatory disorders with inhibitors of bet family bdii bromodomain
WO2019118961A1 (en) Inhibitors for the β-catenin/b-cell lymphoma 9 (bcl9) protein–protein interaction
CN107235960A (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
US20230212174A1 (en) Pyrrolo[2,1-f][1,2,4]triazine derivative and use thereof
WO2026026956A1 (zh) Tacc抑制剂化合物、药物组合物及其制备方法和应用
HK40066884A (zh) 用於治疗癌症的化合物
HK40066884B (zh) 用於治疗癌症的化合物
US20180289664A1 (en) Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors
HK1260375A1 (en) Heterocyclic compounds for the treatment of disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251022